Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603391 · ClinicalTrials.gov registry record · Phase 4
Cannabidiol and CES1 Interactions in Healthy Subjects
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT04603391 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 14 participants.
The verdict
NCT04603391, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The proposed study will assess the drug interaction potential between oral cannabidiol (Epidiolex®) and the carboxylesterase 1 (CES1) substrate methylphenidate (Ritalin®) in 12 healthy research subjects
Interventions
- DRUG dl-Methylphenidate plus Cannabidiol
- DRUG dl-Methylphenidate plus Cannabidiol Placebo solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04603391
The ClinicalTrials.gov registry entry for NCT04603391 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dl-Methylphenidate plus Cannabidiol is the first listed.
NCT04603391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04603391 about?
NCT04603391 is a clinical study titled "Cannabidiol and CES1 Interactions in Healthy Subjects". The proposed study will assess the drug interaction potential between oral cannabidiol (Epidiolex®) and the carboxylesterase 1 (CES1) substrate methylphenidate (Ritalin®) in 12 healthy research subjects
What is the current status of trial NCT04603391?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2021-02-25. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT04603391?
The interventions under investigation include: dl-Methylphenidate plus Cannabidiol (DRUG), dl-Methylphenidate plus Cannabidiol Placebo solution (DRUG).
Who is sponsoring clinical trial NCT04603391?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.